Federated Hermes Inc. Sells 107,719 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Federated Hermes Inc. lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 19.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 435,034 shares of the company's stock after selling 107,719 shares during the period. Federated Hermes Inc.'s holdings in Takeda Pharmaceutical were worth $5,760,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $601,000. QRG Capital Management Inc. boosted its position in Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares during the period. HighTower Advisors LLC grew its position in Takeda Pharmaceutical by 199.5% during the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company's stock worth $1,744,000 after acquiring an additional 81,653 shares during the last quarter. Versant Capital Management Inc purchased a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $26,000. Finally, Franklin Resources Inc. purchased a new position in Takeda Pharmaceutical during the 3rd quarter valued at about $244,000. 9.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.4 %

Shares of NYSE:TAK traded up $0.07 during trading on Thursday, reaching $14.72. 608,340 shares of the stock traded hands, compared to its average volume of 1,844,923. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.37. The stock has a 50-day moving average of $14.52 and a two-hundred day moving average of $13.90. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market cap of $46.82 billion, a P/E ratio of 36.76, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.